HORMONE REPLACEMENT THERAPIES

FEMOSTON® PRODUCT RANGE (17ß-estradiol and dydrogesterone)
When the menstrual cycle a woman has been accustomed to for about forty years becomes less regular and then disappears, the menopause announces a new phase in life. It marks the inevitable end of reproductive capacity and menstrual bleeding. A natural process of change in a woman’s body, but often with considerable consequences. They may be physical as well as mental. Some women don’t experience any complaints at all, but many women do. Just when they are in a dynamic period in life. With children leaving home, having more time for friends and exciting things to do, or at the top of their careers. There is now overwhelming evidence that hormone replacement therapy (HRT) like FEMOSTON®, designed to supplement or replace the missing natural female hormones, can alleviate most, if not all, of these complaints. FEMOSTON® contains two female hormones. Estradiol, the estrogen in FEMOSTON® is identical to natural human estrogen that is lost at menopause. FEMOSTON® is also the only HRT preparation to contain dydrogesterone; a progestogen which works in a similar way to natural progesterone. In contrast to most other progestogens, dydrogesterone does not reverse the beneficial metabolic effects of estradiol.
Hormone replacement therapy can effectively alleviate menopausal symptoms and reduces the risk of osteoporosis, but it has other benefits as well. HRT helps to reduce the risk of cardiovascular disease and Alzheimer, that increases after menopause. Additionally, it increases skin thickness and improves skin quality in postmenopausal women.

	generic name
	brandnames
	product description
	indications
	description of indications
	worldwide availability
	date and country of first launch
	average dosages
	links

generic name
17ß-estradiol and dydrogesterone
[back to top]

brandnames
FEMOSTON®, CLIMASTON®, FEMASTON®
[back to top]

product description
FEMOSTON® (17ß-estradiol and dydrogesterone) is indicated for hormone replacement (menopausal symptoms and prevention of osteoporosis).17ß-estradiol, the estrogen in FEMOSTON®, is identical to natural human estrogen that is lost at menopause. FEMOSTON® is also the only combination hormone replacement therapy to contain dydrogesterone; a progestogen which works in a similar way to natural progesterone.
[back to top]

indications
Menopausal symptoms
Prevention of osteoporosis.
[back to top]

description of indications
Menopausal symptoms
While the hot flushes and night sweats, experienced by around 85 per cent of women, are the most common and therefore the best-known of menopausal symptoms, other physical symptoms include: an urgent and/or frequent need to urinate, vaginal dryness and pain on intercourse, an increased tendency to suffer from vaginal and urinary tract infections, ‘pins and needles’ in hands and feet, joint and muscle pains, headaches, dizziness, shortness of breath and palpitations. Additionally, a menopausal woman may also have to contend with tiredness, loss of energy, insomnia, irritability, anxiety, depression, forgetfulness and inability to concentrate, feelings of inadequacy and mood swings.
[back to top]

Osteoporosis
The term osteoporosis describes bones that have become weak and prone to fracture. Although osteoporosis affects old people of both sexes to some extent, it is much more common in women after the menopause. Osteoporosis is an increasing health problem. One in three postmenopausal women have this condition after the menopause, and half of them will suffer a fracture as a result of it. Osteoporotic fractures exact an enormous cost, in both human and financial terms. Hip fractures need lengthy hospital treatment and a significant proportion of women will be permanently disabled. Osteoporotic fractures of the vertebrae are acutely painful and often lead to loss of height, as well as neck and back deformities. These, in turn, make the sufferer more susceptible to chest and stomach ailments.
[back to top]

worldwide availability
FEMOSTON® (17ß-estradiol and dydrogesterone) is available in more than 30 countries all over the world.
[back to top]

date and country of first launch
1995 in the UK and Netherlands.
[back to top]

average dosages
With all FEMOSTON® dosage forms estradiol is given continuously as a dose of either 1 mg or 2 mg. For sequential treatment, the estrogen is combined with 10 mg dydrogesterone on 14 out of 28 days (FEMOSTON® 1/10 and 2/10). The 2 mg estradiol dosage form is also combined with 20 mg dydrogesterone (FEMOSTON® 2/20).
[back to top]

Links
[back to top]